drugset / Trial / NCT02784106
Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis
Phase 2
Completed
65 enrolled
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently treated with stable dose of methotrexate (MTX).
Timeline
- Start
- 2016-07-31
- Primary completion
- 2017-04-30
- Completion
- 2017-11-14
Outcome
Missed primary endpoint
registry Difference in Proportion of Responders 0.10 (80% CI -0.07 to 0.25) NCT02784106 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evobrutinib | Small molecule | 50 mg | Oral |